Influvac Tetra (B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202)

The vaccine contains inactivated antigens from four influenza virus strains. When injected, these antigens stimulate the immune system to produce specific antibodies against the haemagglutinin and neuraminidase proteins of the included strains, providing active immunity that can neutralise the virus upon future exposure.

The dose of Influvac Tetra is determined by the prescribing healthcare professional based on age, health status and local immunisation guidelines. The vaccine is typically given as a single intramuscular or subcutaneous injection, with repeat dosing as recommended by national health authorities.

Safety data for Influvac Tetra in pregnancy are limited, so the vaccine should only be used if the potential benefits outweigh any potential risks. Breastfeeding is not a contraindication, but women should discuss vaccination with their healthcare provider to make an informed decision.

To order Influvac Tetra, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Influvac Tetra is a quadrivalent, inactivated vaccine that targets two B‑virus lineages, offering broader coverage than trivalent formulations that include only one B strain. Compared with live‑attenuated vaccines, it is administered via injection and is suitable for a wider range of age groups, including those with certain contraindications to live vaccines.

Influvac Tetra must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must never be frozen or shaken. If temperature excursions occur, the product should be inspected for any signs of damage before use.

The vaccine is supplied as an injectable solution and is administered by a qualified healthcare professional via intramuscular or subcutaneous injection, typically into the deltoid muscle of the upper arm or the anterolateral thigh in younger children.

Serious but rare risks include anaphylactic reactions, Guillain‑Barré syndrome, high‑grade fever, seizures and severe allergic responses. Recipients should be observed for at least 15 minutes after injection, and any signs of a serious reaction require immediate medical attention.

Individuals with a known severe allergy to any component of the vaccine, those who have experienced a previous severe reaction to an influenza vaccine, or persons with a history of Guillain‑Barré syndrome within six weeks of a prior influenza vaccination should avoid receiving Influvac Tetra unless advised otherwise by a healthcare professional.